2025 Volume 66 Issue 5 Pages 763-770
This study aimed to investigate the association between brain-derived neurotrophic factor (BDNF) levels and the no-reflow phenomenon in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI).
This retrospective study included 100 patients with STEMI from January 2023 to December 2023. Patients were classified into an observation group (slow flow or no-reflow) and a control group (normal flow) based on the post-PCI Thrombolysis in Myocardial Infarction (TIMI) flow grades.
The observation group exhibited significantly higher BDNF and creatine kinase-MB (CK-MB) levels and significantly lower left ventricular ejection fraction (LVEF) than the control group (P < 0.05). Logistic regression analysis identified diabetes, higher Killip class, lower eGFR, reduced LVEF, multivessel disease, high thrombus burden, elevated B-type natriuretic peptide (BNP), and increased BDNF levels as independent predictors of the no-reflow phenomenon (P < 0.05). Correlation analysis showed that BDNF levels were negatively correlated with TIMI flow grade (r = −0.303, P < 0.01) and LVEF (r = −0.717, P < 0.01) and positively correlated with left ventricular internal dimension in systole (LVIDs; r = 0.509, P < 0.01), STEMI onset time (r = 0.685, P < 0.01), CK-MB (r = 0.689, P < 0.01), TnT (r = 0.708, P < 0.01), and TnI (r = 0.781, P < 0.01).
Higher BDNF levels were significantly associated with impaired myocardial perfusion and reduced cardiac function, as indicated by a lower pre-PCI LVEF. These findings suggest that BDNF may serve as a potential biomarker for the no-reflow phenomenon in patients with STEMI. Further studies are needed to clarify the relationship between BDNF levels and post-PCI recovery of cardiac function.
